RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:A lineage-specific STAT5BN642H mouse model to study NK-cell leukemia.
A lineage-specific STAT5BN642H mouse model to study NK-cell leukemia.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
T细胞和自然杀伤(NK)细胞肿瘤患者常携带体细胞STAT5B功能获得性突变。最常见的STAT5B突变是STAT5BN642H,已知其可驱动小鼠T细胞白血病,但其在NK细胞恶性肿瘤中的作用尚不清楚。将STAT5BN642H突变引入人NK细胞系可增强其在小鼠中诱导白血病的能力。
我们构建了一种可实现STAT5BN642H组织特异性表达的小鼠模型,并选择性地在造血细胞(N642Hvav/+)或仅在NK细胞(N642HNK/NK)中表达突变型STAT5B。所有N642Hvav/+小鼠迅速发生侵袭性T/NKT细胞白血病,而N642HNK/NK小鼠则表现为惰性NK大颗粒淋巴细胞白血病(NK-LGLL),并随年龄增长进展为侵袭性白血病。NK细胞白血病患者的样本具有由突变型STAT5B驱动的独特转录特征,该特征与小鼠白血病性N642HNK/NK NK细胞的转录特征重叠。据我们所知,我们构建了首个可靠的STAT5BN642H驱动的临床前小鼠模型,其表现为惰性NK-LGLL进展为侵袭性NK细胞白血病。这一新型体内工具将使我们能够探索从惰性疾病向侵袭性疾病的转变,从而为NK细胞恶性肿瘤的预防和治疗方案研究提供支持。
Patients with T- and natural killer (NK)-cell neoplasms frequently have somatic STAT5B gain-of-function mutations. The most frequent STAT5B mutation is STAT5BN642H, which is known to drive murine T-cell leukemia, although its role in NK-cell malignancies is unclear. Introduction of the STAT5BN642H mutation into human NK-cell lines enhances their potential to induce leukemia in mice.
We have generated a mouse model that enables tissue-specific expression of STAT5BN642H and have selectively expressed the mutated STAT5B in hematopoietic cells (N642Hvav/+) or exclusively in NK cells (N642HNK/NK). All N642Hvav/+ mice rapidly develop an aggressive T/NKT-cell leukemia, whereas N642HNK/NK mice display an indolent NK-large granular lymphocytic leukemia (NK-LGLL) that progresses to an aggressive leukemia with age.
Samples from patients with NK-cell leukemia have a distinctive transcriptional signature driven by mutant STAT5B, which overlaps with that of murine leukemic N642HNK/NK NK cells. To our knowledge, we have generated the first reliable STAT5BN642H-driven preclinical mouse model that displays an indolent NK-LGLL progressing to aggressive NK-cell leukemia. This novel in vivo tool will enable us to explore the transition from an indolent to an aggressive disease and will thus permit the study of prevention and treatment options for NK-cell malignancies.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。